Adding abiraterone acetate (Zytiga) plus prednisone to standard hormonal therapy for men newly diagnosed with high-risk, metastatic prostate cancer lowers the chance of death by 38%. In a phase III clinical trial of 1,200 ...
Jun 5, 2017
0
0
Patients with metastatic prostate cancer whose PSA levels remain high despite initial hormone treatments have historically had poor prognosis, with survival typically in the 1-2 year range. Results of a 40-person clinical ...
Apr 5, 2017
0
1
In 1048 prostate cancer patients previously treated with docetaxel and 996 metastatic, castration-resistant patients, treatment with the androgen-lowering drug abiraterone acetate (Zytiga) led to longer overall disease control, ...
Dec 3, 2015
0
0
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals ...
Nov 25, 2015
0
9
Abiraterone acetate (abiraterone for short, trade name: Zytiga) has been approved in Germany since December 2012 for men with metastatic prostate cancer that is not responsive to hormone blockade, who only have mild symptoms ...
Jul 2, 2013
0
1
(HealthDay)—For chemotherapy-naive patients with metastatic castration-resistant prostate cancer, abiraterone acetate correlates with improved radiographic progression-free survival, according to a study published online ...
Dec 12, 2012
0
0
Results of a phase 3 trial published in The Lancet Oncology have confirmed that the drug abiraterone acetate (marketed as Zytiga) offers a significant survival benefit to patients with castration-resistant prostate cancer, ...
Sep 17, 2012
0
0
